The company will also implement next-generation high-throughput technologies for drug target discovery and pharmacogenomics applications. RCAT™ adds significant value in the genomics area. It can be used to localize DNA sequences to particular sites on chromosomes, to amplify and isolate DNA sequences without cloning in vivo, and to identify single base-pair genetic differences between individuals. MSI is developing biochips based on RCAT that perform ultra-high throughput Single-Nucleotide Polymorphism (SNP) analysis (both genotyping and haplotyping) for identification of disease genes and drug response genes. Designs for RCAT SNP Chips include arraying thousands of distinct patient samples or tens of thousands of SNPs on a single biochip. RCAT is the only amplification method that can perform direct molecular haplotype analysis. MSI will also utilize its Allele Frequency Distortion technology to rapidly identify genes linked to disease.